Tempest Therapeutics Terminates Material Agreement
Ticker: TPST · Form: 8-K · Filed: Apr 9, 2025 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination, regulation-fd, financial-statements
TL;DR
Tempest Therapeutics terminated a key deal, filing an 8-K on April 8, 2025.
AI Summary
On April 8, 2025, Tempest Therapeutics, Inc. filed an 8-K to report the termination of a material definitive agreement. The filing also includes information regarding Regulation FD disclosure and financial statements and exhibits.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial standing.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can signal underlying business issues or a shift in strategic direction, warranting closer scrutiny.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- April 8, 2025 (date) — Date of earliest event reported
- Millendo Therapeutics, Inc. (company) — Former company name
- OvaScience, Inc. (company) — Former company name
FAQ
What specific material definitive agreement was terminated by Tempest Therapeutics?
The filing does not specify the exact agreement terminated, only that a material definitive agreement was terminated as of April 8, 2025.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, preventing selective disclosure.
What types of financial statements and exhibits are included in this 8-K filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When was Tempest Therapeutics incorporated, and what is its IRS Employer Identification No.?
Tempest Therapeutics was incorporated in Delaware and its IRS Employer Identification No. is 45-1472564.
What were the former names of Tempest Therapeutics, Inc.?
Tempest Therapeutics, Inc. was formerly known as Millendo Therapeutics, Inc. (name change effective December 7, 2018) and prior to that, OvaScience, Inc. (name change effective March 8, 2012).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2025 regarding Tempest Therapeutics, Inc. (TPST).